Dr Mautner needs to treat Noxopharm as a small biotech, rather...

Dr Mautner needs to treat Noxopharm as a small biotech, rather than as a Big Pharma.

It might make Dr Mautner feel good to trumpet her pre-clinical successes, in order to distinguish herself from Professor Kelly, but shareholders deserve to also know the status of clinical trials.

As co-sponsors of the IONIC trial, I expect that both BMS and NOX receive periodic progress reports. As the trial has not been stopped for futility and the number of trial sites has increased, my deduction is that there is at least some evidence of synergy between Veyonda and Opdivo. It would be nice if shareholders were told, for instance, when an interim report might be expected; or whether Noxopharm staff were helping to accelerate the trial.